A Phase 4 interventional study of Risperidone prolonged release in Schizophrenia, sponsored by Janssen-Cilag Ltd.. Completed at 5 sites in Brazil. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 130th largest by enrollment of the 176 interventional ones that give a count, is one of 16 that started in 2006, is one of 47 in phase 4, and was the 173rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18–60
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 12 · Phase 3 74 · Phase 4 47
First in 1996; this study’s year is marked. 16 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 165 across the 176 interventional studies, 541 across the 30 observational. Of the 203 that completed or were terminated, 57 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Ltd. is the lead sponsor of 35 studies on the registry; 4 are open to participants now.
1 of the studies in Schizophrenia by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07615426Janssen Research & Development, LLCA Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia | 2027-06-21 |
Add it to your calendar (.ics) → With an account.
Among the 206 studies in Schizophrenia by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of long-acting risperidone in participants with schizophrenia who have a previous history (in the last 12 months) of bad adherence to the oral antipsychotic treatment of first or second generation. The duration of this study will be 24 weeks and will include following visits: Screening, Baseline, Week 2, 4, 8, 12, 16, 20, 24, 38 and 50 (End visit or early withdrawal). All the eligible participants (after risperidone intolerance test during screening) will receive a dose of 25 milligram risperidone every two weeks by intramuscular injection (injection of a substance into a muscle). Efficacy and safety of the participants will primarily be evaluated by Positive and Negative Syndromes Scale and Extrapyramidal Symptom Rating Scale, respectively. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Drug: Risperidone prolonged release
Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Also known as: - Risperdal consta
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 2
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 4
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 8
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 16
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 24
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 38
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 50
Clinical Global Impressions (CGI) - Disease Severity Score
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Baseline and Week 2, 4, 8, 16, 24, 38 and 50
Extrapyramidal Symptoms Rating Scale (ESRS) Total Score
The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe).
Time frame: Baseline and Week 2, 4, 8, 16, 24 and 50
Drug Attitude Inventory (DAI-10)
The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).
Time frame: Screening, and Week 8, 24 and 50
Short Form-36 (SF-36) - Quality of Life
The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.
Time frame: Baseline and Week 50
Personal and Social Performance (PSP) Scale Score
The PSP scale assesses the degree of a participant's dysfunction (ranging from i \[absent\] to vi \[very severe) within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behavior. The overall score ranges from 1 to 100. Based on the 4-domains there was one total score. Participants with a score of 71 to 100 had a mild degree of difficulty; from 31 to 70, varying degrees of disability; participants with scores of 30 or less function so poorly as to require intensive supervision.
Time frame: Screening, and Week 8, 16, 24, 38 and 50
Global Assessment of Functioning (GAF) Scale Score
The GAF scale is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.
Time frame: Screening, and Week 8, 16, 24, 38 and 50
| Milestone | Risperidone Prolonged Release |
|---|---|
| Started | 53 |
| Completed | 29 |
| Not completed | 24 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 15 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Exacerbation of psychotic symptoms | 1 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2 | 55.53 ± 1.82 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4 | 53.82 ± 1.83 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8 | 51.28 ± 1.86 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16 | 50.55 ± 1.98 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24 | 48.95 ± 2.13 |
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Baseline | 3.55 ± 0.13 |
| Week 2 | 3.37 ± 0.13 |
| Week 4 | 3.30 ± 0.13 |
| Week 8 | 3.21 ± 0.13 |
| Week 16 | 3.10 ± 0.14 |
| Week 24 | 2.92 ± 0.15 |
| Week 38 | 2.94 ± 0.15 |
| Week 50 | 3.19 ± 0.16 |
The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe).
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Baseline | 0.460 ± 0.073 |
| Week 2 | 0.416 ± 0.072 |
| Week 4 | 0.272 ± 0.073 |
| Week 8 | 0.289 ± 0.074 |
| Week 16 | 0.271 ± 0.079 |
| Week 24 | 0.221 ± 0.082 |
| Week 50 | 0.089 ± 0.086 |
The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Screening | 2.78 ± 0.62 |
| Week 8 | 4.45 ± 0.64 |
| Week 24 | 4.59 ± 0.69 |
| Week 50 | 5.07 ± 0.77 |
The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Functional capacity : Baseline | 79.2 ± 21.4 |
| Physical aspect : Baseline | 48.2 ± 40.2 |
| Pain : Baseline | 73.7 ± 27.2 |
| Health General State : Baseline | 60.7 ± 18.4 |
| Vitality : Baseline | 53.8 ± 21.2 |
| Social Aspect : Baseline | 56.1 ± 28.0 |
| Emotional Aspect : Baseline | 34.9 ± 38.4 |
| Mental Health : Baseline | 58.9 ± 21.9 |
| Functional capacity : Week 50 | 67.9 ± 31.6 |
| Physical aspect : Week 50 | 52.9 ± 41.3 |
| Pain : Week 50 | 75.4 ± 29.5 |
| Health General State : Week 50 | 62.7 ± 19.5 |
| Vitality : Week 50 | 53.1 ± 18.3 |
| Social Aspect : Week 50 | 59.9 ± 26.2 |
| Emotional Aspect : Week 50 | 55.0 ± 41.7 |
| Mental Health : Week 50 | 56.6 ± 20.6 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38 | 47.40 ± 2.26 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50 | 49.72 ± 2.32 |
The PSP scale assesses the degree of a participant's dysfunction (ranging from i \[absent\] to vi \[very severe) within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behavior. The overall score ranges from 1 to 100. Based on the 4-domains there was one total score. Participants with a score of 71 to 100 had a mild degree of difficulty; from 31 to 70, varying degrees of disability; participants with scores of 30 or less function so poorly as to require intensive supervision.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Screening | 60.0 ± 2.9 |
| Week 8 | 66.4 ± 2.4 |
| Week 16 | 72.6 ± 2.3 |
| Week 24 | 71.7 ± 2.1 |
| Week 38 | 71.8 ± 2.1 |
| Week 50 | 69.1 ± 2.2 |
The GAF scale is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.
| Units on a scale | Risperidone Prolonged Release |
|---|---|
| Screening | 62.6 ± 3.1 |
| Week 8 | 67.5 ± 2.6 |
| Week 16 | 72.5 ± 2.5 |
| Week 24 | 71.4 ± 2.3 |
| Week 38 | 73.9 ± 2.3 |
| Week 50 | 68.6 ± 2.3 |
Collected over Baseline up to Week 50. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risperidone Prolonged Release | — | 3/53 (5.7%) | 40/53 (75.5%) |
| Event | Risperidone Prolonged Release |
|---|---|
| Psychomotor hyperactivityNervous system disorders | 1/53 |
| Psychotic disorderPsychiatric disorders | 1/53 |
| SchizophreniaPsychiatric disorders | 1/53 |
| Event | Risperidone Prolonged Release |
|---|---|
| Libido decreasedPsychiatric disorders | 12/53 |
| Weight increasedInvestigations | 7/53 |
| Blood prolactin increasedInvestigations | 6/53 |
| AnxietyPsychiatric disorders | 4/53 |
| Schizophrenia, disorganised typePsychiatric disorders | 4/53 |
| HyperprolactinaemiaEndocrine disorders | 3/53 |
| Abdominal pain upperGastrointestinal disorders | 3/53 |
| Decreased appetiteMetabolism and nutrition disorders | 3/53 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 3/53 |
| SchizophreniaPsychiatric disorders | 3/53 |
| Age, Continuous(Years) | Risperidone Prolonged Release |
|---|---|
| Mean | 33.6 ± 9.1 |
| Sex: Female, Male(Participants) | Risperidone Prolonged Release |
|---|---|
| Female | 14 |
| Male | 39 |
| Positive and Negative Syndromes Scale (PANSS) Total Score(Units on a scale) | Risperidone Prolonged Release |
|---|---|
| Mean | 58.80 ± 1.82 |
The record gives a start of Jan 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.